Vertex Pharma (VRTX) Tops Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vertex (VRTX) Q1 Quiet, But Reimbursement Commentary 'Encouraging'; Leerink Says; PT Up to $150
April 30, 2015 6:18 AM EDTLeerink Partners analyst Howard Liang reiterated an Outperform rating and boosted his price target on Vertex (NASDAQ: VRTX) to $150.00 (from $131.00) following a "quiet" quarter as reimbursement commentary was encouraging.
Liang commented, "VRTX reported roughly in-line Kalydeco sales for 1Q:15 ($130M vs. our/consensus estimates of $127M/$131M).... More
